Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction:insights from BIOSTAT-CHF and ASIAN-HF registries by Ouwerkerk, Wouter et al.
                                                                    
University of Dundee
Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker
treatment on outcomes in heart failure with reduced ejection fraction
Ouwerkerk, Wouter; Teng, Tiew-Hwa K.; Tromp, Jasper ; Tay, Wan Ting; Cleland, John G.;
van Veldhuisen, Dirk J.
Published in:







Link to publication in Discovery Research Portal
Citation for published version (APA):
Ouwerkerk, W., Teng, T-H. K., Tromp, J., Tay, W. T., Cleland, J. G., van Veldhuisen, D. J., Dickstein, K., Ng, L.
L., Lang, C. C., Anker, S. D., Zannad, F., Hung, C-L., Sawhney, J. P. S., Naik, A., Shimizu, W., Hagiwara, N.,
Wander, G. S., Anand, I., Richards, A. M., ... Lam, C. S. P. (2020). Effects of combined renin-angiotensin-
aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection
fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. European Journal of Heart Failure, 22(8), 1472-
1482. https://doi.org/10.1002/ejhf.1869
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 08. Dec. 2021
1 
Effects of combined RAAS inhibitor and beta-blocker treatment on outcomes in heart 1 
failure with reduced ejection fraction: Insights from BIOSTAT-CHF and ASIAN-HF 2 
registries 3 
4 
†Wouter Ouwerkerk PhD1,2, †Tiew-Hwa K Teng PhD1,3,4, Jasper Tromp MD PhD 1,4,5, Wan Ting Tay MSc1, John G. Cleland MD 5 
PhD6, Dirk J. van Veldhuisen MD PhD4, Kenneth Dickstein MD PhD7,8, Leong L. Ng MD PhD9,  6 
 Chim C. Lang MD PhD10, Stefan D. Anker, MD PhD11, Faiez Zannad MD PhD12, Chung-Lieh Hung MD PhD13,14, J.P.S. 7 
Sawhney MD PhD15, Ajay Naik MD PhD16, Wataru Shimizu MD PhD17, Nobuhisa Hagiwara MD PhD18 , Gurpreet Singh Wander 8 
MD PhD19, Inder Anand MD PhD20*, A Mark Richards MD PhD21,22, Adriaan A. Voors MD PhD4, Carolyn S.P. Lam MD 9 
PhD**1,4,5 10 
11 
†Co-primary authors 12 
*on behalf of the ASIAN-HF investigators, Appendix S113 
** Corresponding author14 
15 
1. National Heart Centre Singapore,16 
2. Dept of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam,17 
The Netherlands18 
3. School of Population and Global Health, University of Western Australia, WA, Australia19 
4. Duke–National University of Singapore Medical School, Singapore, Singapore20 
5. University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, the Netherlands21 
6. National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, United Kingdom.22 
7. University of Bergen, Bergen, Norway23 
8. Stavanger University Hospital, Stavanger, Norway24 
9. Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield25 
Hospital, Groby Road Leicester, LE3 9QP, United Kingdom26 
10 School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of27 
Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, United Kingdom28 
11 Division of Cardiology and Metabolism-Heart Failure, Cachexia & Sarcopenia; Department of Cardiology (CVK), Berlin-29 
Brandenburg Center for Regenerative Therapies (BCRT), Charite´ University Medicine, Charite’pl. 1, 10117 Berlin, Germany30 
12. Inserm CIC-P 1433, Université de Lorraine, CHRU de Nancy, FCRIN INI-CRCT, Nancy, France31 
13 Cardiovascular Division, Brigham and Women's Hospital, Boston, M, United States of America.32 
14 Division of Cardiology, Departments of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan33 
15 Sir Gangaram Hospital, New Delhi, India.34 
16 CIMS Hospital, Ahmedabad, Gujarat, India.35 
17 Department of Cardiology. Tokyo Women`s Medical University 8-1 Kawada-cho, Shinjuku-ku, Tokyo36 
18 Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School37 
19 Dayanand Medical College and Hospital, Ludhiana, Punjab, India38 
20 Veterans Affairs Medical Center, Minneapolis, MN, United States of America.39 
21 Cardiovascular Research Institute, National University Heart Centre, Singapore, Singapore40 
22 University of Otago, Dunedin, New Zealand41 
42 
ClinicalTrials.gov Identifier: NCT01633398 43 
Total word count: 3,022 main text (+2,399 for references and figure legends) 44 






This is the peer reviewed version of the following article: Ouwerkerk, W., et al. "Effects of combined renin–angiotensin–
aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights 
from BIOSTAT‐CHF and ASIAN‐HF registries", European Journal of Hearth Failure (2020), which has been published in 
final form at https://doi.org/10.1002/ejhf.1869. This article may be used for non-commercial purposes in accordance with 
Wiley Terms and Conditions for Self-Archiving.
2 
1 
Corresponding author: Professor Carolyn S. P. Lam. MBBS, MD, PhD 2 
National Heart Centre Singapore. 3 
5 Hospital Dr, Singapore 169609, Singapore. 4 




Key Points 1 
Question: Are better outcomes associated with lower combined doses of both ACEi/ARB and β-2 
blockers, versus the high target doses of either β-blockers or ACEi/ARBs alone, and which 3 
should have priority during up-titration? 4 
Findings: In our cohort study we found that lower dose of combined therapy was associated with 5 
better outcomes than guideline recommended target doses of either monotherapy. Up-titrating β-6 
blockers was associated with a consistent and greater reduction in hazards of all-cause mortality 7 
(HR for 100% GRTD: 0.40, 95% CI 0.25-0.63, compared to no treatment) than corresponding 8 
ACEi/ARB up-titration (HR: 0.75, 95% CI 0.53-1.07). 9 
Meaning: Achieving lower doses of both β-blocker and ACEi/ARB was associated with better 10 
outcome than high dose of monotherapy, where up-titrating β-blockers to target dose resulted in 11 





Background. Angiotensin-converting-enzyme inhibitors (ACEi)/Angiotensin receptor blockers 2 
(ARB) and β-blockers are guideline-recommended first-line therapies in heart-failure with 3 
reduced ejection fraction (HFrEF). Previous studies showed that individual drug classes were 4 
under-dosed in many parts of Europe and Asia. In this study we investigated the association of 5 
combined up-titration of ACEi/ARBs and β-blockers on all-cause mortality and its combination 6 
with hospitalization for HF. 7 
 8 
Methods and Results. 6,787 HFrEF patients (mean age 62.6 ±13.2 years, 77.7% men, mean 9 
LVEF 27.7 ±7.2%) were enrolled in prospective multinational European (BIOSTAT-CHF; 10 
n=2,100) and Asian (ASIAN-HF; n= 4,687) studies. Outcomes were analysed according to 11 
achieved % guideline-recommended target doses (GRTD) of combination ACEi/ARB and β-12 
blocker therapy, adjusted for indication bias. 13 
 14 
Results. Only 14% (n=981) patients achieved ≥50% GRTD for both ACEi/ARB and β-blocker. 15 
Best outcomes were observed in patients who achieved 100% GRTD of both ACEi/ARB and β-16 
blocker (HR 0.32, 95% CI 0.26-0.39 vs. none). Lower dose of combined therapy was associated 17 
with better outcomes than 100% GRTD of either monotherapy. Up-titrating β-blockers was 18 
associated with a consistent and greater reduction in hazards of all-cause mortality (HR for 100% 19 
GRTD: 0.40, 95% CI 0.25-0.63) than corresponding ACEi/ARB up-titration (HR: 0.75, 95% CI 20 





Conclusion.  1 
This study shows that best outcomes were observed in patients attaining GRTD for both 2 
ACEi/ARB and β-blockers, unfortunately this was rarely achieved. Achieving >50% GRTD of 3 
both drug classes was associated with better outcome than target dose of monotherapy. Up-4 
titrating β-blockers to target dose was associated with greater mortality reduction than up-titrating 5 
ACEi/ARB.  6 
 7 
 8 
Key words: 9 
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 11 
Translational Perspective: Our findings can inform clinical practice, particularly when 12 
managing sick patients with multi-morbidity requiring polypharmacy. Best outcomes are 13 
obtained with 100% GRTDs, however, under circumstances when it is challenging to up-titrate 14 
both ACEi/ARB and β-blockers, achieving moderate doses of both drug classes is more 15 
important than reaching maximal target doses of only one class of drug, and further up-titrating 16 
β-blockers to 100% GRTD may be associated with greater mortality benefit than up-titrating 17 




Current international guidelines1,2 recommend up-titration of evidence-based medications 2 
[angiotensin-converting enzyme-inhibitors (ACEi)/angiotensin II receptor blockers (ARB) and β-3 
blocker] in patients with heart failure and reduced ejection fraction (HFrEF) to target doses used 4 
in clinical trials. The recommendations are based on evidence from large randomized clinical 5 
trials that both ACEi and β-blockers, up-titrated to respective target doses, improve clinical 6 
outcomes in patients with mild to moderate HFrEF3–13. Furthermore, studies directly comparing 7 
low versus high doses showed (trends towards) superiority of higher doses of ACEi/ARB and β-8 
blocker compared with lower doses14–16. However, in daily clinical practice, patients often fail to 9 
achieve guideline-recommended target doses (GRTD)17–21. Patients with HF frequently have 10 
multiple comorbidities and require polypharmacy, making it challenging to successfully up-titrate 11 
multiple classes of HF medications22.  12 
Previous studies showed that individual drug classes of ACEi/ARB and β-blocker were under-13 
dosed among patients with HFrEF in many parts of Europe and Asia20,21. However, we did not 14 
previously examine the effect of combination therapies on outcomes. In the current study, we 15 
aimed to determine the association of combined up-titration of ACEi/ARB and β-blockers with 16 
the first occurrence of all-cause mortality or hospitalization for HF and all-cause mortality in 17 
patients with HFrEF. Specifically, we aimed to address two key questions in clinical practice: 18 
1. Are better outcomes associated with lower combined doses of both ACEi/ARB and β-19 
blockers, versus the high target doses of either β-blockers or ACEi/ARBs alone? 20 
2. In combination therapy of both β-blockers and ACEi/ARBs, which one (i.e. ACEi/ARB 21 
or β-blocker) should have priority during up-titration? 22 
7 
 
Such practical questions are very unlikely to be answered in further large randomized controlled 1 
trials, but yet are clinically very relevant to day-to-day practice. We therefore sought to provide 2 
the best available evidence from real world data to guide these clinically important decisions.  3 
 4 
Methods 5 
Patient population 6 
The design of BIOSTAT-CHF and ASIAN-HF registry have been published23–25. In brief, 7 
BIOSTAT-CHF23 enrolled 2,516 adult patients with HFrEF (left ventricular ejection fraction 8 
[LVEF] ≤40%) from 69 participating centres in 11 European countries. The ASIAN-HF 9 
registry24,26 is a multinational registry including 5,276 adult patients with HFrEF (LVEF ≤40%) 10 
from 46 investigation sites across 11 regions in Asia. All patients had symptoms and signs of HF 11 
and objective evidence of reduced LVEF, and were followed up for clinical outcomes of death 12 
and hospitalization. Ethics approvals were obtained from the local institutional review committee 13 
of each participating centre and all participating subjects gave informed consent. This study 14 
conforms to the ethical guidelines as laid down in the Declaration of Helsinki. 15 
 16 
Medication and data collection 17 
HF medications and their target doses were defined according to ESC guidelines1,27. Maximum 18 
total daily doses attained during follow-up were calculated as a percentage of the guideline-19 
recommended target daily doses (GRTD). Doses were grouped into four categories (0%, 1–49%, 20 
50-99% and ≥100% of GRTD per drug class, resulting in 16 possible treatment group 21 
combinations of ACEi/ARB and β-blocker. Patients were considered successfully up-titrated 22 
when ≥50% recommended target doses for both ACEi/ARBs and β-blockers were achieved after 23 
8 
 
up-titration1,27. While the use (versus non-use) of mineralocorticoid receptor antagonists (MRA) 1 
was considered, no specific MRA up-titration strategy was used in BIOSTAT-CHF or ASIAN-2 
HF. We therefore did not include MRA dosage up-titration in our analyses, but corrected for 3 
MRA prescription. 4 
 5 
Outcomes 6 
The primary outcome of interest was the composite of all-cause mortality or hospitalization for 7 
HF. We also assessed all-cause mortality alone and admission to hospital because of worsening 8 
HF as secondary outcomes. Events were adjudicated by an adjudication committee in ASIAN-9 
HF, but in BIOSTAT-CHF, adjudication was done by the treating physicians. However, a 10 
systematic meta-analysis failed to detect any effect of event adjudication on study conclusions of 11 
cardiovascular outcome trials and the numbers of events included in the final analyses were 12 
minimally changed28. 13 
 14 
Statistical analysis 15 
We analysed data from 16 groups of patients achieving combinations of 0%, 1–49%, 50-99% and 16 
≥100% of GRTD of ACEi/ARB and β-blocker. In order to have enough statistical power in all 16 17 
treatment groups, we combined both ASIAN-HF and BIOSTAT-CHF cohorts. We corrected for 18 
being included in either ASIAN-HF or BIOSTAT-CHF in all analyses. Results for each group 19 
were summarized using standard descriptive statistics including, as appropriate, mean ± standard 20 
deviation (SD) and median plus 25th-75th percentiles or numbers and percentages. We tested 21 
differences between groups using the Kruskal-Wallis test (for contiguous variables) or the χ² test 22 
(for categorical variables). 23 
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Recognizing that both BIOSTAT-CHF and ASIAN-HF were observational non-randomized 1 
studies, we were careful to adjust for treatment indication bias in outcome analysis. We used 2 
three methods for adjustment: Propensity score matching, inverse probability weighting with the 3 
probability to reach recommended dose and a multivariable analysis with treatment dose as 4 
covariate. We only reported results of inverse probability weighting because all methods showed 5 
similar results. All analyses for the effects of ACEi/ARB and β-blocker treatment were inversely 6 
weighted for the probability of achieving ≥50% GRTD29,30. These weights were calculated by the 7 
mean probability per patient across all imputation sets, predicted by a penalized logistic model. 8 
For the penalized (LASSO) logistic regression analysis predicting successful treatment, we 9 
included a comprehensive list of 41 clinical variables (Table S1). Heart rate at baseline was also 10 
included in the models correcting for treatment indication bias. To prevent overfit of our 11 
statistical models, we used the LASSO regression analyses to select the most parsimonious 12 
model31,32. All variables were normalized using Box-Cox transformations where necessary33,34. 13 
Missing values were imputed 5 times using multi-chain Monte Carlo methods Gibbs sampling35. 14 
We did 10-fold cross validation to ensure optimal penalty parameters and used all analyses for 15 
each imputed dataset36,37.  16 
We used multivariable Cox proportional hazards regression models to examine the association of 17 
percentage of GRTD prescribed (0%, 1–49%, 50-99% and ≥100%) by therapeutic class and their 18 
interactions with outcome, corrected for the different cohorts. For the HF-hospitalization analysis 19 
a competing risk analysis was performed with all-cause mortality as competing risk. Furthermore, 20 
to investigate the differences between sex, we undertook stratified Cox proportional hazards 21 
models on sex. 22 
10 
 
A two-tailed p-value of <0.05 was considered statistically significant. Statistical analyses were 1 
conducted using R, A Language and Environment for Statistical Computing, version 3.5.0 (R 2 




From a total of 7,792 patients (2,516 from BIOSTAT-CHF and 5,276 from ASIAN-HF), 6,787 2 
patients with LVEF ≤ 40% and information on ACEi/ARB and β-blocker up-titration (2,100 from 3 
BIOSTAT-CHF and 4,687 from ASIAN-HF, mean age 62.6 ±13.2 years, 77.7% men, mean 4 
LVEF 27.7 ±7.21%) were included in this analysis. Median follow-up of 2,100 patients from 5 
BIOSTAT-CHF (22 months [25th-75th percentile 17-27 months] was similar to that in 4,687 6 
patients from ASIAN-HF (21 [11-25] months) (Supplementary Figure S1). Patients from both 7 
cohorts were predominantly older men with a history of hypertension and ischaemic aetiology of 8 
HF; however patients from ASIAN-HF were on average ~7 years younger with lower body mass 9 
index (25 vs 28 kg/m2), less atrial fibrillation (19 vs 43%) but more diabetes (41 vs 32%) 10 
compared to those from BIOSTAT-CHF. Although there was a lower proportion of patients with 11 
severe [New York Heart Association (NYHA) class III/IV] symptoms in ASIAN-HF (34 vs 12 
60%), more patients in ASIAN-HF had HF hospitalization within the past year compared to 13 
BIOSTAT-CHF (63 vs 32%) (Table S2). All subsequent analyses corrected for cohort.  14 
Baseline characteristics of patients achieving the different treatment dose combinations of 15 
guideline-recommended ACEi/ARB and β-blocker target doses are presented in Table 1 (selected 16 
dose groups to illustrate characteristics of patients with predominant ACEi/ARB vs β-blocker up-17 
titration) and Table S3 (all 16 groups of dose combinations of the two drug classes). As expected, 18 
compared to patients not receiving the drug or receiving only low doses, patients who achieved 19 
higher doses were younger, had higher blood pressure and better renal function (for ACEi/ARB 20 
up-titration) at baseline, and were more likely to have a history of hypertension or myocardial 21 
infarction but less likely to have a history of chronic obstructive pulmonary disease (for β-blocker 22 
up-titration). Among the 41 clinical variables included in multivariable models, country of 23 
12 
 
origin/enrolment, younger age, higher systolic/diastolic blood pressure, hypertension, current 1 
smoking and history of myocardial infarction were significant independent predictors which were 2 
positively associated with attainment of ≥50% GRTD for either therapeutic class. In contrast, the 3 
presence of peripheral oedema, higher NYHA class, chronic obstructive pulmonary disease and 4 
increasing serum creatinine levels were negatively associated with attainment of GRTDs (Table 5 
S4). This model had an AUC of 0.72 and 0.71 when correcting for optimism. 6 
Of the 6,787 patients, only 14% (n= 981) patients achieved ≥50% GRTD and 3% (n=190) 7 
achieved 100% GRTD for both ACEi/ARB and β-blocker (Table 2). The majority (52%) of 8 
patients only achieved 1-49% of the GRTD of β-blockers, regardless of ACEi/ARB, with little 9 
heterogeneity between BIOSTAT-CHF and ASIAN-HF sub-cohorts (Figure 1).  10 
 11 
Association of achieved dose (0%, 1-49%, 50-99% and ≥100%) with all-cause mortality or heart 12 
failure-related hospitalization 13 
After adjusting for indication bias and correcting for cohorts, increasing doses towards 14 
recommended ACEi/ARB and β-blocker doses were generally associated with a decreasing risk 15 
of a composite outcome (mortality or heart failure hospitalization), Figure 2a. When any dose (up 16 
to 49% GRTD) was given for both ACEi/ARB and β-blocker, the hazard of composite outcome 17 
was lower (Hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.61-0.84) compared with none 18 
(Table 2). Increasing the doses further to 50-99% GRTD for either ACEi/ARB or β-blocker in 19 
combination therapy reduced the hazards markedly (HR 0.50/0.61). Of note, the reduction in 20 
hazards observed for these combinations, even though not reaching 100% GRTD in either drug 21 
class, was greater than that observed with the attainment of 100% GRTD for ACEi/ARB alone 22 
(HR 0.71, 95% CI 0.52-0.96) or 100% GRTD for β-blocker alone (HR 0.68, 95% CI 0.49-23 
13 
 
0.93)(Table 2). Treating patients at sub-optimal ACE/ARB and BB doses (1-49% of GDMT) 1 
appears not to be better than treating patients at high dose of either single therapy. However, as 2 
soon as one of the treatment doses is increased to at least 50% of guideline dose, the risks reduce 3 
to 0.61 (95% CI 0.49-0.75) and 0.50 (95% CI 0.42-0.61) which is lower than 0.67 and 0.71 for 4 
the groups with <50% GDMT. Achievement of 100% of recommended doses for ACEi/ARB and 5 
β-blockers was associated with the lowest hazard ratios (HR 0.32 CI 0.26-0.39). Correcting for 6 
MRA prescription did not alter the risks of the separate treatment groups. Sex modified the 7 
association of medication doses with composite outcomes (p=0.001). In stratified analyses, for all 8 
outcomes, women benefited more at lower doses than men, even with sub-optimal doses of <50% 9 
GRTD (supplementary table S5). 10 
 11 
Association of achieved dose (0%, 1-49%, 50-99% and ≥100%) with all-cause mortality 12 
Compared to patients not treated with ACEi/ARB and β-blockers, the lowest risk in all-cause 13 
mortality was observed in those achieving 100% GRTD for both therapeutic classes (with HR 14 
0.19, 95% CI 0.14-0.24, Table 2, Figure 2b). The second lowest risk HR 0.27 (95% CI 0.21-0.34) 15 
was among those with 50-99% target dose for ACEi/ARB and 100% target dose for β-blockers. 16 
As monotherapy, achievement of 100% GRTD for ACEi/ARB was not associated with additional 17 
mortality benefit compared to lower doses of ACEi/ARB; in contrast, increasing doses of β-18 
blockers as monotherapy was associated with steady reduction in hazards for mortality (from HR 19 
0.75 [95% CI 0.6-0.92] with 1-49% GRTD, to 0.65 [95% CI, 0.48-0.87] with 50-99% GRTD, to 20 
0.4 [95% CI 0.25-0.63] with 100% GRTD).  21 
  22 
14 
 
Association of achieved dose (0%, 1-49%, 50-99% and ≥100%) with HF-related hospitalization 1 
Increasing doses of combinations of ACE-inhibitors/ARBs and β-blockers were not directly 2 
associated with risk of HF-hospitalization (Table 2, Figure 2c), although a lower risk was seen in 3 
patients with increasing dose of single therapy of ACE-inhibitors/ARBs.  4 
 5 
Discussion 6 
Our key findings from our multinational observational studies are: In both Europe and Asia, 7 
achievement of full GRTD for both ACEi/ARB and β-blockers was rare. Not surprisingly, the 8 
best outcomes were observed in those who achieved 100% GRTD of combined therapy. 9 
However, in the vast majority of patients not reaching 100% GRTD, taking any dose combination 10 
was better than none, and achieving lower doses of both drug classes was associated with better 11 
outcomes than reaching the highest dose of only one class. For mortality reduction, up-titrating β-12 
blockers to 100% GRTD was associated with greater benefit than up-titrating ACEi/ARB to 13 
100% GRTD. The key practical questions we sought to answer in this study are very unlikely to 14 
be answered in large randomized controlled trials, yet very relevant to day-to-day clinical 15 
practice. In RCTs, novel drugs are given on top of standard of care. However, regarding standard 16 
of care, the main outcome papers of these RCTs only provide data on whether 17 
ACEi/ARB/BB/MRA etc are used or not (yes/no) but the doses as percentage of the guideline-18 
recommended target doses are never reported. In this paper these data are provided which makes 19 
them even more important. 20 
There are few previous reports on the doses of first-line evidence-based pharmacotherapy in 21 
HFrEF patients 20,21,38–40. Despite robust evidence showing the benefits of attainment of GRTD of 22 
ACEi/ARB14,16 and β-blockers 15,41,42 , many studies report failure to achieve guideline-target 23 
15 
 
doses in usual care setting20,21,38,39,43,44, and even in the trial setting, with  CIBIS-II10, CIBIS-1 
ELD45 and HF-ACTION46 showing that  ≤25% to ≤50%, of patients achieve target doses of β-2 
blockers42. Reasons for failure to achieve guideline-targeted doses are multifactorial and include 3 
patients’ clinical status, drug intolerance or adverse effects (for instance hypotension, 4 
bradycardia, renal impairment, hyperkalaemia, and other real or perceived side effects), 5 
physicians’ prescribing patterns, polypharmacy and lack of compliance, as well as cost 6 
constraints47. Our results are consistent with contemporary US-based data, with the recently 7 
reported CHAMP-HF (Change the Management of Patients with Heart Failure) registry38,39 8 
showing that <20% of eligible patients were receiving target doses of ACEi/ARBs and β-9 
blockers, even among those with systolic blood pressure ≥110 mm Hg, and a remarkably low 1% 10 
of patients receiving target doses of ACEi/ARBs, β-blockers and MRAs. The CHAMP-HF 11 
registry also systematically analysed reasons for lack of up-titration of medications and found 12 
that among those who were treated with ACEi/ARBs, higher systolic blood pressure and a history 13 
of hypertension (for ACEi/ARBs), black race, and obesity/diabetes (for β-blockers) were 14 
associated with achieving target doses; whereas prior HF hospitalization within 12 months, 15 
asthma/ chronic obstructive pulmonary disease, and NYHA functional class III/IV status were 16 
associated with sub-target doses. For all-cause mortality, graduated decreases in relative risk of 17 
deaths with increasing doses of ACEi/ARBs and beta-blockers were observed (Figure 2b). In 18 
contrast, the association of high doses of medications observed in HFH (Figure 2c), could 19 
potentially stem from other non-medical factors, e.g. limited access to care; differences in health 20 
care systems across geography, particularly in regard to coordinated primary care following 21 
discharge; variation in delivery and quality of cardiac care, and others as reported in the 22 
QUALIFY international registry48–50. 23 
16 
 
In light of the known challenges in day-to-day practice of achieving 100% target doses of 1 
combination therapies in HFrEF, our results emphasize that “some is better than none”. These 2 
results add to that of studies in the SOLVD and CIBIS II trials, which showed the effects of low 3 
dose enalapril51 or bisoprolol52 as single therapy. The TRED-HF trial53 showed that withdrawal 4 
of treatment studied the effect of evidence-based medical treatment withdrawal. All studies show 5 
that patients already benefit from small doses of guideline-directed medical therapies. Thus, 6 
initiating and maintaining guideline-directed medical therapies in patients with HFrEF remains a 7 
quintessential aim in the management of these patients, even when target dose is not reached. 8 
 9 
However, how do we manage dose titration in cases where full target doses of combination drugs 10 
cannot be achieved (for instance when blood pressure is borderline)? Our results suggest that up-11 
titration to even sub-target doses of both ACEi/ARBs and β-blockers was associated with better 12 
outcomes than full up-titration to 100% target doses of a single drug class (with either none or 13 
very low doses of the other drug class). This is not to say that attempts at up-titration are not 14 
important in real world practice; on the contrary we showed that achievement of higher doses of 15 
both guideline-recommended drug classes was associated with reduction in composite outcomes 16 
of death and HF hospitalization, consistent with prior trial evidence comparing lower versus 17 
higher doses of guideline-directed medical therapies. In the ATLAS trial14, treatment with high 18 
(32.5 to 35mg) vs low (2.5 to 5mg) daily doses lisinopril was associated with a non-significant 19 
8% lower hazard of death but a significant 12% lower risk of all-cause death or hospitalization, 20 
and 24% fewer hospitalizations for HF. Similar findings were found in the HEAAL trial, with the 21 
use of low dose (50mg) vs. high dose (150mg) losartan16. In both trials, symptomatic 22 
hypotension/syncope and renal insufficiency, and hyperkalaemia (only in HEAAL trial), were 23 
17 
 
more prevalent in the high dose group. The Multicenter Carvedilol Heart Failure Dose 1 
Assessment (MUCHA) trial54 was undertaken to establish the efficacy and safety of two doses 2 
(low-5mg/day; high-20mg/day) of long-term carvedilol vs. placebo, in Japanese patients with HF 3 
and LVEF ≤40%. There was no statistical difference in outcomes between the high and low dose 4 
of carvediolol. High (≥25 mg/day) vs. low dose (<25 mg/day) carvedilol equivalents in HF-5 
ACTION also conferred similar benefit for all-cause mortality and CV outcomes, although high 6 
dose was superior (albeit with marginal significance) for a composite outcome of all-cause 7 
mortality or HF hospitalization38,39. Our results build on these prior trials and suggest that when 8 
faced with the clinical conundrum of up-titrating both drugs versus up-titrating only one of the 9 
drugs to maximal target doses, the former may be a preferable approach. Furthermore, we 10 
observed that up-titrating β-blockers to 100% GRTD was associated with mortality benefit, even 11 
when doses of ACEi/ARB were still sub-target. As a cautionary note, the guidelines advised slow 12 
uptitration of β-blockers due to a possible transient HF worsening during the first 2 weeks after 13 
upstart with β-blockers. 14 
 15 
This contemporary prospective multinational study spans a huge geography in Europe and Asia. 16 
Both studies were designed with a specific investigator-directed question regarding reasons for 17 
not achieving recommended doses; however, in a large proportion of cases there was a lack of 18 
further specification of the reason for not achieving GRTD other than ‘unknown’. Specific 19 
contraindications to further uptitration of medications were not captured, although those with 20 
absolute contraindications to ACEi/ARBs at baseline remained small. The impact of incident 21 
renal failure on discontinuation of treatment could not been examined.  22 
  23 
18 
 
Robust statistical analytical methods were used and we corrected for indication bias; 1 
unfortunately, if this correction was sufficient is untestable and there remains potential for 2 
residual bias. We further acknowledge that lack of persistence and adherence to medications may 3 
play a role, but cannot be directly measured in our study. We were unable to assess the change in 4 
heart rate with up-titration of β-blockers. While concurrent use of MRAs were accounted for (vs 5 
non-use), we did not assess different doses of MRAs. Nonetheless, our observation ‘real world’ 6 
data from large cohorts may provide the best available evidence to guide clinically important 7 
decisions which are unlikely to be tested in future large randomized controlled trials. 8 
 9 
Conclusions 10 
Our multinational real-world data suggest that although best outcomes were observed in patients 11 
attaining 100% GRTD for both ACEi/ARB and β-blockers, such combined maximal up-titration 12 
was rarely achieved. Achieving lower doses of both drug classes to at least 50% GRTD was 13 
associated with better outcomes than reaching the target dose of only one class; and further up-14 
titrating β-blockers to 100% GRTD was associated with greater mortality benefit than up-titrating 15 
ACEi/ARB. Our data suggest that less is better than nothing, but since this is not a randomized 16 
controlled trial, no strong recommendations can be made. The only recommendation that can be 17 
made is that ACEi/ARB and beta-blockers should be uptitrated to the recommended doses as 18 
stated in all heart failure guidelines. 19 
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Figure 1: Distribution of ACEi/ARB and β-blocker in ASIAN-HF and BIOSTAT-CHF 
 
Figure 2 A: Hazard Ratio of mortality and/or HF-related hospitalization for patients achieving a 
combination of 0, 1-49, 50-99% and ≥100% recommended treatment dose of ACEi/ARB and β-
blocker dose; B: Hazard Ratio of mortality for patients achieving a combination of 0, 1-49, 50-
99% and ≥100% recommended treatment dose of ACEi/ARB and β-blocker dose; C: Hazard Ratio 
of HF-related hospitalization for patients achieving a combination of 0, 1-49, 50-99% and ≥100% 
recommended treatment dose of ACEi/ARB and β-blocker dose; 
 
 
Table 1: Baseline characteristics of patients achieving low dose, high dose and target dose of guideline recommended treatment 
Variable All A0B0 A0B1 A0B2 A0B3 
P for trend 
B1 to B3 
(A0) 




A3 (B0) Other 
n 6787 502 782 245 133  380 234 135 - 4376 
n (ASIAN-HF) 
4687 
(69.1%) 482 (96%) 656 (83.9%) 203 (82.9%) 115 (86.5%) <0.0001 320 (84.2%) 189 (80.8%) 118 (87.4%) <0.0001 2604 (59.5%) 
Sex (Male) 
5271 
(77.7%) 376 (74.9%) 615 (78.6%) 192 (78.4%) 101 (75.9%) 0.43 290 (76.3%) 174 (74.4%) 98 (72.6%) 0.84 3425 (78.3%) 
Age (years) 62.6 (13.16) 63.9 (13.13) 63.9 (13.49) 61.3 (14.37) 60.4 (13.85) 0.001 63.4 (13.85) 62.4 (12.82) 59.7 (14.23) 0.002 62.3 (12.9) 
Former smoker 
2504 
(36.9%) 146 (29.1%) 265 (33.9%) 101 (41.2%) 53 (39.8%) 0.001 131 (34.5%) 78 (33.3%) 32 (23.7%) 0.14 1698 (38.8%) 
Current smoker 913 (13.5%) 44 (8.8%) 103 (13.2%) 21 (8.6%) 17 (12.8%)  42 (11.1%) 23 (9.8%) 13 (9.6%)  650 (14.9%) 
Chronic obstructive pulmonary disease 726 (10.7%) 68 (13.7%) 81 (10.4%) 27 (11%) 12 (9%) 0.25 52 (13.7%) 39 (16.7%) 18 (13.3%) 0.69 429 (9.8%) 
Myocardial infarction 
2211 
(48.1%) 151 (53.9%) 275 (54.3%) 82 (56.6%) 50 (59.5%) 0.79 123 (53%) 69 (52.3%) 40 (59.7%) 0.77 1421 (45.1%) 
Ischaemic aetiology 
3343 
(51.4%) 226 (50.1%) 417 (56.3%) 115 (50%) 69 (56.1%) 0.12 199 (55.6%) 115 (50.7%) 60 (48.4%) 0.35 2142 (50.5%) 
NYHA Class III/IV 
2691 
(42.7%) 193 (50%) 352 (50.1%) 106 (45.7%) 50 (41%) 0.2 158 (45.9%) 89 (40.6%) 45 (35.7%) 0.018 1698 (40.8%) 
Peripheral oedema 
2058 
(30.4%) 122 (24.6%) 216 (27.6%) 68 (27.8%) 37 (27.8%) 0.64 128 (33.7%) 73 (31.2%) 44 (32.6%) 0.02 1370 (31.3%) 
Orthopnea 
1664 
(24.5%) 140 (28.1%) 210 (26.9%) 56 (22.9%) 37 (27.8%) 0.49 102 (26.8%) 58 (24.8%) 36 (26.7%) 0.83 1025 (23.4%) 
Pulmonary rales 951 (16.7%) 76 (15.5%) 116 (15.9%) 35 (15.2%) 20 (15.9%) 1 79 (21.9%) 50 (23.9%) 31 (25%) 0.013 544 (15.9%) 
Previous HF-hospitalization in past year 
2247 
(48.8%) 184 (66.4%) 327 (60.2%) 99 (57.6%) 57 (60.6%) 0.22 131 (60.4%) 64 (47.8%) 42 (47.7%) <0.0001 1343 (43.5%) 
Atrial Fibrillation 1765 (26%) 102 (20.5%) 197 (25.2%) 80 (32.7%) 33 (24.8%) 0.004 87 (22.9%) 38 (16.2%) 15 (11.1%) 0.013 1213 (27.7%) 
Diabetes mellitus 
2607 
(38.4%) 199 (40%) 339 (43.4%) 94 (38.4%) 67 (50.4%) 0.09 149 (39.2%) 90 (38.5%) 59 (43.7%) 0.78 1610 (36.8%) 
Hypertension 
3708 
(54.7%) 273 (54.8%) 429 (54.9%) 145 (59.2%) 80 (60.2%) 0.45 163 (42.9%) 99 (42.3%) 63 (46.7%) 0.001 2456 (56.2%) 
Body mass index (kg/m2) 25.9 (5.4) 24.3 (4.73) 24.6 (4.96) 25.8 (5.33) 25.2 (4.97) 0.001 24.5 (4.92) 25.5 (5.11) 26.5 (7.45) <0.0001 26.4 (5.44) 
Heart rate (beats/min) 79.6 (17.26) 82.8 (18.17) 78.5 (16.72) 78.3 (16.01) 80 (17.28) 0.004 82 (18.46) 82.1 (18.48) 81.9 (18.69) 0.55 79.1 (17.03) 




(19.46) 119.3 (19) 
119.6 
(20.66) 0.33 121.1 (20.86) 
Diastolic blood pressure (mmHg) 73.1 (12.74) 72.5 (12.72) 70.5 (11.7) 73.3 (12.15) 73.8 (13.44) 0.21 70.2 (12.01) 72.5 (11.77) 73.8 (12.6) 0.41 73.8 (12.96) 























eGFR (ml/min/1.73m2) 68.2 (28.64) 58.2 (28.88) 59.7 (30.59) 60.5 (29.39) 59.4 (30.15) 0.44 66.6 (28.68) 72 (27.77) 71.3 (23.83) <0.0001 71.3 (27.63) 




    
 
     
 B0=BB 0%; B1=BB 1-49%; B2=BB-50-99%; B3=BB≥100%         
 p=statistical differences between the subgroups         
Table 2: Hazard ratio (95% confidence interval) of patients achieving specific target dose 
for Mortality or HF-hospitalization, Mortality and HF-hospitalization 
 
  Mortality or HF-hospitalization 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB 1.00 (reference) 0.98 (0.83-1.17; 0.85) 0.90 (0.71-1.15; 0.41) 0.68 (0.49-0.93; 0.02) 
1-49% ACEi/ARB 0.90 (0.73-1.10; 0.30) 0.71 (0.61-0.84; <0.001) 0.61 (0.49-0.75; <0.001 0.80 (0.62-1.04; 0.10) 
50-99% ACEi/ARB 0.67 (0.52-0.87; 0.002) 0.50 (0.42-0.61; <0.001) 0.64 (0.54-0.75; <0.001) 0.57 (0.48-0.68; <0.001) 
100% ACEi/ARB 0.71 (0.52-0.96; 0.03) 0.52 (0.42-0.64; <0.001) 0.66 (0.56-0.77; <0.001) 0.32 (0.26-0.39; <0.001) 
  Mortality 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB 1.00 (reference) 0.75 (0.60-0.92; 0.006) 0.65 (0.48-0.87; 0.004) 0.40 (0.25-0.63; <0.001) 
1-49% ACEi/ARB 0.74 (0.57-0.95; 0.02) 0.57 (0.47-0.69; <0.001) 0.39 (0.29-0.51; <0.001) 0.58 (0.42-0.81; 0.001) 
50-99% ACEi/ARB 0.57 (0.42-0.78; <0.001) 0.33 (0.26-0.42; <0.001) 0.42 (0.34-0.51; <0.001) 0.27 (0.21-0.34; <0.001) 
100% ACEi/ARB 0.75 (0.53-1.07; 0.11) 0.40 (0.30-0.52; <0.001) 0.38 (0.31-0.46; <0.001) 0.19 (0.14-0.24; <0.001) 
 HF-hospitalization 
 0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB 1.00 (reference) 1.42 (1.14-1.77; 0.002) 1.48 (1.12-1.95; 0.006) 1.10 (0.76-1.59; 0.62) 
1-49% ACEi/ARB 1.26 (0.97-1.63;0.08) 1.08 (0.88-1.33; 0.43) 0.94 (0.72-1.21; 0.64) 1.14 (0.83-1.57; 0.41) 
50-99% ACEi/ARB 0.80 (0.57-1.11; 0.18) 0.75 (0.59-0.95; 0.02) 0.93 (0.76-1.14; 0.50) 1.14 (0.92-1.41; 0.22) 






Table S1: Variables used in inverse probability weighting 
Variable  Summary Percentage missing 
n 6787 11 % 
ASIAN-HF 4687 (69.1%) 0 % 
East Asia 1544 (22.7%) 0 % 
South Asia 1314 (19.4%)  
South-East Asia 1829 (26.9%)  
North EU 950 (14%)  
South EU 1150 (16.9%)  
Country (China) 440 (6.5%) 0 % 
Country (Hong Kong) 50 (0.7%)  
Country (India) 1314 (19.4%)  
Country (Indonesia) 158 (2.3%)  
Country (Japan) 527 (7.8%)  
Country (Korea) 272 (4%)  
Country (Malaysia) 490 (7.2%)  
Country (Philippines) 24 (0.4%)  
Country (Singapore) 1030 (15.2%)  
Country (Taiwan) 255 (3.8%)  
Country (Thailand) 127 (1.9%)  
Country (Netherlands) 276 (4.1%)  
Country (Germany) 84 (1.2%)  
Country (France) 195 (2.9%)  
Country (Greece) 278 (4.1%)  
Country (Italy) 289 (4.3%)  
Country (Norway) 93 (1.4%)  
Country (Poland) 244 (3.6%)  
Country (Serbia) 366 (5.4%)  
Country (Slovenia) 22 (0.3%)  
Country (Sweden) 96 (1.4%)  
Country (UK) 157 (2.3%)  
Age (years) 62.6 (13.16) 0 % 
Sex (Male) 5271 (77.7%) 0 % 
Race (Caucasian) 2078 (30.6%) 0 % 
Race (Chinese) 1475 (21.7%)  
Race (Indians) 1505 (22.2%)  
Race (Malay) 651 (9.6%)  
Race (Japanese) 528 (7.8%)  
Race (Korean) 272 (4%)  
Race (Thai) 127 (1.9%)  
Race (Filipino) 9 (0.1%)  
Race (Indigenous SEA) 106 (1.6%)  
Race (Other) 33 (0.5%)  
NYHA class 1 633 (10.1%) 7 % 
NYHA class 2 2972 (47.2%)  
NYHA class 3 2199 (34.9%)  
NYHA class 4 492 (7.8%)  
Orthopnea present 1664 (24.5%) 0 % 
Height (m) 166.4 (9.54) 3 % 
Weight (kg) 72.2 (18.11) 3 % 
BMI (kg/m2) 25.9 (5.4) 3 % 
Heart rate (beats/min) 79.6 (17.26) 1 % 
Systolic blood pressure (mmHg) 120 (20.58) 0 % 
Diastolic blood pressure (mmHg) 73.1 (12.74) 0 % 
jugular venous pressure 1132 (18.6%) 10 % 
Peripheral oedema 2058 (30.4%) 0 % 
Rales 951 (16.7%) 16 % 
Hepatomegaly 542 (8%) 0 % 
Ischemic aetiology 3343 (51.4%) 4 % 
Previous hospitalization for heart failure 2247 (48.8%) 32 % 
Device therapy (ICD only) 368 (5.4%) 0 % 
Device therapy (Pacemaker only) 260 (3.8%)  
Device therapy (Biventricular Pacer only) 124 (1.8%)  
Device therapy (Biventricular Pacer and ICD) 464 (6.9%)  
Coronary artery disease 3336 (49.2%) 0 % 
Myocardial infarction 2211 (48.1%) 32 % 
Percutaneous coronary intervention 1390 (30.3%) 32 % 
Valvular surgery 717 (15.6%) 32 % 
Atrial Fibrillation 1765 (26%) 0 % 
Hypertension 3708 (54.7%) 0 % 
Stroke 502 (7.4%) 0 % 
Peripheral artery disease 378 (5.6%) 0 % 
Chronic obstructive pulmonary disease 726 (10.7%) 0 % 
Diabetes mellitus 2607 (38.4%) 0 % 
Smoking (Ever) 2504 (36.9%) 0 % 
Smoking (Never) 913 (13.5%)  
Alcohol history 1139 (16.8%) 0 % 
Serum Creatinine (mol/L) 4.7 (0.44) 14 % 
Estimated GFR, calculated with MDRD 68.2 (28.64) 15 % 
Sodium (mmol/L) 138.6 (4.03) 20 % 
Potassium (mmol/L) 4.3 (0.56) 17 % 
Haemoglobin (g/dL) 13.2 (2.01) 20 % 
Blood Urea Nitroge n(mmol/L) 10.3 (8.78) 33 % 
log-NT-proBNP (ng/L) 8.2 (7.45-9) 68 % 
log-BNP (ng/L) 6.3 (5.23-7.28) 85 % 
LVEF (%) 28 (22-34) 3 % 
 
  
Table S2: Baseline characteristics for ASIAN-HF and BIOSTAT-CHF cohorts 
 
Variable ASIAN.HF BIOSTAT-CHF p value excluded ASIAN-HF excluded BIOSTAT-CHF 
n  4687  2100  589 416 
Sex (Male) 3682 (78.6%) 1589 (75.7%) 0.008 441 (74.9%) 257 (61.8%) 
Age (years) 60.3 (13.03) 67.7 (11.95) <0.0001 58.7 (13.19) 75 (9.97) 
Ischaemic aetiology 2189 (49.8%) 1154 (55%) 0.0001 281 (51.5%) 204 (49%) 
NYHA Class III/IV 1455 (34.3%) 1236 (60.3%) <0.0001 213 (39.6%) 286 (72.2%) 
peripheral oedema 1070 (22.9%) 988 (47%) <0.0001 171 (30.1%) 268 (64.4%) 
Orthopnea 986 (21.1%) 678 (32.3%) <0.0001 200 (35.1%) 201 (48.6%) 
pulmonary rales 768 (16.4%) 183 (18%) 0.22 111 (19.5%) 65 (23.8%) 
Previous HF-hospitalization in past 
year 1578 (62.9%) 669 (31.9%) <0.0001 193 (65%) 125 (30%) 
Atrial Fibrillation 864 (18.5%) 901 (42.9%) <0.0001 77 (13.6%) 242 (58.2%) 
Diabetes mellitus 1931 (41.2%) 676 (32.2%) <0.0001 189 (33.3%) 143 (34.4%) 
Hypertension 2431 (51.9%) 1277 (60.8%) <0.0001 288 (50.8%) 292 (70.2%) 
Body mass index (kg/m^2) 24.9 (5.06) 28 (5.52) <0.0001 24.6 (5.51) 27.4 (5.34) 
Heart rate (beats/min) 79.5 (16.19) 79.8 (19.43) 0.51 80.9 (15.84) 80.8 (19.71) 
Systolic blood pressure (mmHg) 118.1 (19.99) 124.2 (21.24) <0.0001 121.1 (20.03) 127.3 (24.85) 
Diastolic blood pressure (mmHg) 72 (12.45) 75.5 (13.05) <0.0001 75.2 (13.19) 71.9 (14.52) 
LVEF (%) 27.3 (7.06) 28.6 (7.49) <0.0001 28.1 (22-34) 45 (35-55) 
NT-proBNP (ng/L) 3294 (1436-8103) 4024 (2253-8185) <0.0001 4023 (1339-11849) 4495 (2713-9000) 
eGFR (ml/min/1.73m^2) 66.1 (27.85) 71.9 (29.65) <0.0001 63 (27.11) 64.2 (28.79) 
Combined Endpoint 1441 (31%) 741 (35%)    
All-cause mortality 864 (18%) 423 (20%)    
Heart failure hospitalization 1119 (24%) 500 (24%)    
 
 
Table S3: Baseline characteristics of groups achieving 0%, 1-49%, 50-99% and 100% guideline recommended target doses for ACE-
inhibitor/ARB and beta-blocker 
Variable All A0B0 A0B1 A0B2 A0B3 A1B0 A1B1 A1B2 A1B3 
n 6787 502 782 245 133 380 1524 458 185 
n (ASIAN-HF) 4687 (69.1%) 482 (96%) 656 (83.9%) 203 (82.9%) 115 (86.5%) 320 (84.2%) 1049 (68.8%) 305 (66.6%) 134 (72.4%) 
Sex (Male) 5271 (77.7%) 376 (74.9%) 615 (78.6%) 192 (78.4%) 101 (75.9%) 290 (76.3%) 1188 (78%) 366 (79.9%) 151 (81.6%) 
Age (years) 62.6 (13.16) 63.9 (13.13) 63.9 (13.49) 61.3 (14.37) 60.4 (13.85) 63.4 (13.85) 62.1 (12.95) 62.3 (12.59) 61.5 (12.49) 
Former smoker 2504 (36.9%) 146 (29.1%) 265 (33.9%) 101 (41.2%) 53 (39.8%) 131 (34.5%) 567 (37.2%) 156 (34.1%) 86 (46.5%) 
Current smoker 913 (13.5%) 44 (8.8%) 103 (13.2%) 21 (8.6%) 17 (12.8%) 42 (11.1%) 257 (16.9%) 71 (15.5%) 23 (12.4%) 
Chronic obstructive pulmonary 
disease 726 (10.7%) 68 (13.7%) 81 (10.4%) 27 (11%) 12 (9%) 52 (13.7%) 154 (10.1%) 47 (10.3%) 13 (7%) 
Myocardial infarction 2211 (48.1%) 151 (53.9%) 275 (54.3%) 82 (56.6%) 50 (59.5%) 123 (53%) 492 (46.9%) 139 (45.3%) 61 (47.3%) 
Ischaemic aetiology 3343 (51.4%) 226 (50.1%) 417 (56.3%) 115 (50%) 69 (56.1%) 199 (55.6%) 740 (50.4%) 219 (49.5%) 93 (52.8%) 
NYHA Class III/IV 2691 (42.7%) 193 (50%) 352 (50.1%) 106 (45.7%) 50 (41%) 158 (45.9%) 571 (40.2%) 157 (36%) 53 (29.8%) 
Peripheral oedema 2058 (30.4%) 122 (24.6%) 216 (27.6%) 68 (27.8%) 37 (27.8%) 128 (33.7%) 463 (30.4%) 135 (29.5%) 58 (31.4%) 
Orthopnea 1664 (24.5%) 140 (28.1%) 210 (26.9%) 56 (22.9%) 37 (27.8%) 102 (26.8%) 348 (22.9%) 101 (22.1%) 42 (22.7%) 
Pulmonary rales 951 (16.7%) 76 (15.5%) 116 (15.9%) 35 (15.2%) 20 (15.9%) 79 (21.9%) 222 (17.1%) 51 (13.5%) 17 (11%) 
Previous HF-hospitalization in past 
year 2247 (48.8%) 184 (66.4%) 327 (60.2%) 99 (57.6%) 57 (60.6%) 131 (60.4%) 470 (49%) 141 (45.2%) 73 (55.3%) 
Atrial Fibrillation 1765 (26%) 102 (20.5%) 197 (25.2%) 80 (32.7%) 33 (24.8%) 87 (22.9%) 403 (26.5%) 148 (32.3%) 74 (40%) 
Diabetes mellitus 2607 (38.4%) 199 (40%) 339 (43.4%) 94 (38.4%) 67 (50.4%) 149 (39.2%) 539 (35.4%) 177 (38.6%) 82 (44.3%) 
Hypertension 3708 (54.7%) 273 (54.8%) 429 (54.9%) 145 (59.2%) 80 (60.2%) 163 (42.9%) 740 (48.6%) 239 (52.2%) 112 (60.5%) 
Body mass index (kg/m^2) 25.9 (5.4) 24.3 (4.73) 24.6 (4.96) 25.8 (5.33) 25.2 (4.97) 24.5 (4.92) 25.3 (5.02) 25.9 (4.91) 26.4 (5.34) 
Heart rate (beats/min) 79.6 (17.26) 82.8 (18.17) 78.5 (16.72) 78.3 (16.01) 80 (17.28) 82 (18.46) 78.5 (16.51) 78.8 (15.9) 80.9 (18.27) 
Systolic blood pressure (mmHg) 120 (20.58) 118.1 (21.1) 116.4 (18.45) 120.9 (21.3) 121.4 (21.38) 115.4 (19.46) 115.8 (18.71) 118.3 (20.28) 119.8 (19.2) 
Diastolic blood pressure (mmHg) 73.1 (12.74) 72.5 (12.72) 70.5 (11.7) 73.3 (12.15) 73.8 (13.44) 70.2 (12.01) 70.5 (11.95) 72.6 (12.78) 71.7 (12.83) 


















eGFR (ml/min/1.73m^2) 68.2 (28.64) 58.2 (28.88) 59.7 (30.59) 60.5 (29.39) 59.4 (30.15) 66.6 (28.68) 70.8 (27.43) 69.4 (28.78) 62.9 (27.16) 
Potassium (mmol/L) 6787 4.2 (0.64) 4.3 (0.55) 4.3 (0.56) 4.3 (0.57) 4.2 (0.53) 4.2 (0.54) 4.3 (0.57) 4.2 (0.52) 
MRA use at baseline  173 (34%) 410 (52%) 146 (60%) 77 (58%) 214 (56%) 952 (62%) 280 (61%) 109 (59%) 
A0=ACEi/ARB 0%;A1=ACEi/ARB 1-49%; A2=ACEi/ARB-50-99%; A3=ACEi/ARB≥100%    
B0=BB 0%; B1=BB 1-49%; B2=BB-50-99%; B3=BB≥100%  
     
 
  
Variable A2B0 A2B1 A2B2 A2B3 A3B0 A3B1 A3B2 A3B3 p 
n 234 797 340 178 135 431 273 190  
n (ASIAN-HF) 189 (80.8%) 428 (53.7%) 160 (47.1%) 109 (61.2%) 118 (87.4%) 201 (46.6%) 120 (44%) 98 (51.6%) <0.0001 
Sex (Male) 174 (74.4%) 619 (77.7%) 268 (78.8%) 135 (75.8%) 98 (72.6%) 334 (77.5%) 219 (80.2%) 145 (76.3%) 0.7 
Age (years) 62.4 (12.82) 63.1 (12.73) 61.9 (13.09) 59.7 (14.27) 59.7 (14.23) 64.6 (12.47) 62.2 (12.26) 59.9 (13.71) <0.0001 
Former smoker 78 (33.3%) 292 (36.6%) 155 (45.6%) 80 (44.9%) 32 (23.7%) 170 (39.4%) 112 (41%) 80 (42.1%) <0.0001 
Current smoker 23 (9.8%) 110 (13.8%) 50 (14.7%) 22 (12.4%) 13 (9.6%) 53 (12.3%) 40 (14.7%) 24 (12.6%)  
Chronic obstructive pulmonary 
disease 39 (16.7%) 84 (10.5%) 31 (9.1%) 14 (7.9%) 18 (13.3%) 41 (9.5%) 28 (10.3%) 17 (8.9%) 0.047 
Myocardial infarction 69 (52.3%) 264 (44.7%) 123 (45.4%) 58 (49.2%) 40 (59.7%) 143 (42.1%) 89 (42.2%) 52 (38%) 0.0001 
Ischaemic aetiology 115 (50.7%) 395 (50.3%) 185 (55.7%) 88 (51.5%) 60 (48.4%) 217 (51.3%) 129 (48.9%) 76 (41.3%) 0.07 
NYHA Class III/IV 89 (40.6%) 340 (44.4%) 134 (41.2%) 65 (38%) 45 (35.7%) 191 (45.6%) 117 (44.2%) 70 (37.6%) <0.0001 
Peripheral oedema 73 (31.2%) 242 (30.4%) 117 (34.4%) 48 (27%) 44 (32.6%) 152 (35.3%) 96 (35.2%) 59 (31.1%) 0.039 
Orthopnea 58 (24.8%) 205 (25.7%) 77 (22.6%) 39 (21.9%) 36 (26.7%) 114 (26.5%) 61 (22.3%) 38 (20%) 0.27 
Pulmonary rales 50 (23.9%) 104 (17.5%) 35 (15.2%) 18 (12.7%) 31 (25%) 56 (17.8%) 28 (15.2%) 13 (9.8%) 0.002 
Previous HF-hospitalization in past 
year 64 (47.8%) 244 (40.8%) 104 (40.8%) 60 (44.8%) 42 (47.7%) 104 (32.2%) 83 (37.6%) 64 (42.7%) <0.0001 
Atrial Fibrillation 38 (16.2%) 180 (22.6%) 93 (27.4%) 57 (32%) 15 (11.1%) 111 (25.8%) 88 (32.2%) 59 (31.1%) <0.0001 
Diabetes mellitus 90 (38.5%) 282 (35.4%) 118 (34.7%) 75 (42.1%) 59 (43.7%) 167 (38.7%) 95 (34.8%) 75 (39.5%) 0.003 
Hypertension 99 (42.3%) 464 (58.3%) 203 (59.7%) 112 (62.9%) 63 (46.7%) 289 (67.1%) 176 (64.5%) 121 (63.7%) <0.0001 
Body mass index (kg/m^2) 25.5 (5.11) 26.4 (5.01) 27.6 (6.18) 27.9 (5.19) 26.5 (7.45) 27.3 (5.89) 28.4 (6.02) 28.4 (6.15) <0.0001 
Heart rate (beats/min) 82.1 (18.48) 78.7 (16.63) 79.6 (17.23) 81.9 (19) 81.9 (18.69) 78.7 (17.13) 79.2 (17.92) 81.8 (19.77) <0.0001 
Systolic blood pressure (mmHg) 119.3 (19) 122.1 (20.15) 125.9 (20.65) 123.3 (19.4) 119.6 (20.66) 128.8 (23.46) 127.7 (21.89) 130.5 (23.5) <0.0001 
Diastolic blood pressure (mmHg) 72.5 (11.77) 74.6 (12.45) 76.3 (12.32) 76.3 (12.25) 73.8 (12.6) 77.5 (13.19) 79.2 (14.68) 79.5 (13.76) <0.0001 


















eGFR (ml/min/1.73m^2) 72 (27.77) 72.2 (25.86) 73.3 (26.06) 69.7 (28.3) 71.3 (23.83) 74 (29.45) 71.9 (28.5) 75.6 (28.64) <0.0001 
Potassium (mmol/L) 4.2 (0.58) 4.3 (0.56) 4.3 (0.53) 4.2 (0.55) 4.3 (0.62) 4.3 (0.59) 4.3 (0.53) 4.3 (0.49) 0.4695 
MRA use 124 (53%) 481 (60%) 185 (54%) 97 (54%) 78 (58%) 249 (58%) 160 (59%) 109 (57%) <0.001 
A0=ACEi/ARB 0%;A1=ACEi/ARB 1-49%; A2=ACEi/ARB-50-99%; A3=ACEi/ARB≥100% 
B0=BB 0%; B1=BB 1-49%; B2=BB-50-99%; B3=BB≥100% 
 
  
Table S4: Results of multivariate logistic analyses predicting attainment of ≥50% GRTD for either ACEi/ARB or β-blockers 
 
Variable OR 95% CI p-value 
(Intercept) 0.00 (0-30.45) 0.11 
Country (China) - - - 
Country (Hong Kong) 12.48 (3.88-40.10) <0.0001 
Country (India) 6.78 (3.07-14.96) <0.0001 
Country (Indonesia) 11.80 (4.73-29.46) <0.0001 
Country (Japan) 3.15 (1.29-7.69) 0.01 
Country (Korea) 25.78 (11.39-58.35) <0.0001 
Country (Malaysia) 14.21 (6.33-31.94) <0.0001 
Country (Philippines) 6.58 (1.26-34.41) 0.03 
Country (Singapore) 7.94 (3.57-17.65) <0.0001 
Country (Taiwan) 3.94 (1.55-9.99) 0.004 
Country (Thailand) 9.10 (3.51-23.61) <0.0001 
Country (Netherlands) 32.56 (14.20-74.63) <0.0001 
Country (Germany) 25.64 (10.08-65.22) <0.0001 
Country (France) 39.42 (17.09-90.89) <0.0001 
Country (Greece) 3.23 (1.27-8.22) 0.01 
Country (Italy) 15.82 (6.81-36.78) <0.0001 
Country (Norway) 37.68 (15.33-92.61) <0.0001 
Country (Poland) 17.24 (7.44-39.96) <0.0001 
Country (Serbia) 12.72 (5.62-28.78) <0.0001 
Country (Slovenia) 31.65 (9.70-103.22) <0.0001 
Country (Sweden) 71.73 (29.56-174.05) <0.0001 
Country (UK) 8.82 (3.46-22.50) <0.0001 
Age (years) 0.98 (0.97-0.99) <0.0001 
Sex (male) 1.06 (0.83-1.35) 0.63 
LVEF (%) 1.00 (0.99-1.01) 0.65 
HF-hospitalization in year before inclusion 0.87 (0.71-1.06) 0.16 
Orthopnea present 0.83 (0.67-1.03) 0.1 
Height (m) 1.01 (0.98-1.04) 0.52 
Weight (kg) 1.01 (0.98-1.04) 0.56 
Body mass index (kg/m2) 1.02 (0.94-1.11) 0.64 
Rales 0.91 (0.72-1.16) 0.46 
Ischemic aetiology 0.90 (0.74-1.08) 0.26 
Percutaneous coronary intervention  1.14 (0.95-1.38) 0.17 
Alcohol usage 1.02 (0.83-1.25) 0.84 
NYHA class I - - - 
NYHA class II 0.83 (0.64-1.08) 0.16 
NYHA class III 0.83 (0.62-1.11) 0.2 
NYHA class IV 0.58 (0.37-0.91) 0.02 
Myocardial infarction 1.21 (1.00-1.47) 0.048 
Heart Rate (bpm) 1.00 (0.99-1.00) 0.27 
Systolic blood pressure (mmHg) 1.01 (1.00-1.01) <0.0001 
Diastolic blood pressure (mmHg) 1.01 (1.00-1.02) 0.013 
Peripheral oedema present 0.82 (0.69-0.99) 0.037 
Atrial Fibrillation 1.09 (0.91-1.31) 0.33 
Hypertension 1.31 (1.11-1.55) 0.0017 
Peripheral Artery Disease 0.76 (0.54-1.07) 0.11 
Chronic obstructive pulmonary disease  0.76 (0.58-0.98) 0.03 
Smoking (never) - - - 
Smoking (current) 1.20 (1.00-1.43) 0.0495 
Smokin (ever) 1.00 (0.78-1.28) 0.99 
log-B-type natriuretic peptide (ng/L) 0.99 (0.93-1.04) 0.59 
Hemoglobin (g/dL) 1.02 (0.97-1.06) 0.46 
eGFR (ml/min/1.73m2) 0.99 (0.99-1.00) 0.056 
serum Creatinine mol/L 0.49 (0.29-0.83) 0.008 
Sodium (mmol/L) 1.01 (0.99-1.04) 0.31 
Potassium (mmol/L) 1.16 (1.01-1.34) 0.04 
Blood Urea Nitrogen (mmol/L) 1.00 (0.98-1.01) 0.71 
log-N-terminal-pro-BNP (ng/L) 0.96 (0.89-1.03) 0.23 
 
Table S5: Hazard ratio (95% confidence interval) of patients achieving specific target dose 
for Mortality or HF-hospitalization, Mortality and HF-hospitalization stratified by sex. 
 
MEN Mortality or HF-hospitalization 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB - 0.94 (0.77-1.15; 0.55) 0.87 (0.67-1.14; 0.32) 0.60 (0.41-0.88; 0.01) 
1-49% ACEi/ARB 0.89 (0.71-1.13; 0.35) 0.74 (0.62-0.89; 0.001) 0.62 (0.49-0.79; <0.001) 0.78 (0.58-1.04; 0.09) 
50-99% ACEi/ARB 0.62 (0.46-0.83; 0.002) 0.51 (0.41-0.63; <0.001) 0.70 (0.59-0.84; <0.001) 0.56 (0.46-0.69; <0.001) 
100% ACEi/ARB 0.60 (0.41-0.88; 0.008) 0.50 (0.39-0.64; <0.001) 0.63 (0.52-0.75; <0.001) 0.31 (0.25-0.39; <0.001) 
  Mortality 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB - 0.73 (0.57-0.93; 0.01) 0.64 (0.45-0.91; 0.01) 0.37 (0.21-0.63; <0.001) 
1-49% ACEi/ARB 0.75 (0.56-1.00; 0.05) 0.64 (0.51-0.80; <0.001) 0.40 (0.30-0.55; <0.001) 0.63 (0.43-0.91; 0.01) 
50-99% ACEi/ARB 0.56 (0.39-0.81; 0.002) 0.35 (0.27-0.46; <0.001) 0.49 (0.40-0.61; <0.001) 0.29 (0.22-0.38; <0.001) 
100% ACEi/ARB 0.74 (0.49-1.13; 0.16) 0.42 (0.31-0.57; <0.001) 0.39 (0.31-0.50; <0.001) 0.15 (0.11-0.21; <0.001) 
  HF-hospitalization 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB - 1.44 (1.11-1.87; 0.006) 1.59 (1.14-2.21; 0.006) 1.16 (0.74-1.82; 0.51) 
1-49% ACEi/ARB 1.39 (1.03-1.88; 0.03) 1.18 (0.92-1.50; 0.19) 1.02 (0.76-1.39; 0.88) 1.22 (0.84-1.78; 0.30) 
50-99% ACEi/ARB 0.82 (0.55-1.23; 0.33) 0.85 (0.64-1.12; 0.25) 0.91 (0.65-1.27; 0.57) 1.11 (0.75-1.65; 0.61) 
100% ACEi/ARB 0.68 (0.4-1.16; 0.15) 0.88 (0.64-1.21; 0.41) 1.05 (0.74-1.48; 0.80) 0.81 (0.53-1.24; 0.33) 
WOMEN Mortality or HF-hospitalization 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB - 1.11 (0.77-1.61; 0.58) 1.00 (0.61-1.65; 0.99) 0.94 (0.51-1.74; 0.84) 
1-49% ACEi/ARB 0.88 (0.56-1.38; 0.59) 0.59 (0.41-0.84; 0.003) 0.51 (0.31-0.84; 0.008) 0.86 (0.47-1.55; 0.61) 
50-99% ACEi/ARB 0.85 (0.51-1.42; 0.54) 0.47 (0.31-0.71; <0.001) 0.43 (0.30-0.61; <0.001) 0.56 (0.39-0.82; 0.003) 
100% ACEi/ARB 1.06 (0.61-1.86; 0.83) 0.58 (0.37-0.91; 0.02) 0.77 (0.55-1.09; 0.1416) 0.35 (0.24-0.53; <0.001) 
  Mortality 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB - 0.79 (0.52-1.20; 0.27) 0.67 (0.37-1.22; 0.194 0.47 (0.21-1.06; 0.07) 
1-49% ACEi/ARB 0.71 (0.43-1.19; 0.19) 0.34 (0.23-0.52; <0.001) 0.33 (0.18-0.60; <0.001) 0.44 (0.20-0.96; 0.04) 
50-99% ACEi/ARB 0.58 (0.32-1.05; 0.07) 0.28 (0.17-0.45; <0.001) 0.21 (0.14-0.32; <0.001) 0.22 (0.14-0.36; <0.001) 
100% ACEi/ARB 0.74 (0.49-1.13; 0.16) 0.42 (0.31-0.57; <0.001) 0.39 (0.31-0.50; <0.001) 0.15 (0.11-0.21; <0.001) 
  HF-hospitalization 
  0% BB 1-49% BB 50-99% BB 100% BB 
0% ACEi/ARB - 1.68 (1.00-2.82; 0.05) 1.88 (0.98-3.60; 0.057) 1.62 (0.72-3.65; 0.25) 
1-49% ACEi/ARB 1.18 (0.62-2.23; 0.62) 1.34 (0.83-2.18; 0.23) 1.40 (0.76-2.59; 0.2791) 1.51 (0.67-3.40; 0.32) 
50-99% ACEi/ARB 1.26 (0.62-2.56; 0.53) 0.99 (0.57-1.72; 0.97) 0.88 (0.43-1.83; 0.7355) 1.63 (0.79-3.39; 0.19) 
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